Tiziana Biagioli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tiziana Biagioli has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Fanelli
General Laboratory, Azienda Ospedaliero-Universitaria Careggi, 50134 Florence, Italy
3 shared publications - Luisa Lanzilao
General Laboratory, Azienda Ospedaliero-Universitaria Careggi, 50134 Florence, Italy
3 shared publications - Alessandra Celli
Clinical Pathology Laboratory Unit, San Jacopo Hospital, Azienda USL Toscana Centro, 51100 Pistoia, Italy
2 shared publications - Anna Maria Grazia Gelli
Clinical Pathology Laboratory Unit, S. Giuseppe Hospital, Azienda USL Toscana Centro, 50053 Empoli, Italy
2 shared publications - Edda Russo
Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy
2 shared publications - Enza Aiello
Clinical Pathology Laboratory Unit, S. Giuseppe Hospital, Azienda USL Toscana Centro, 50053 Empoli, Italy
2 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (20) , 3397
Hidden Signals in Serum Protein Electrophoresis: Artificial Intelligence from Laboratory Pattern Recognition to Clinical Validation
Serum protein electrophoresis (SPE) remains a central laboratory method for the detection and characterization of monoclonal gammopathies and other dysproteinemic patterns. Despite substantial analytical automation, interpretation still relies largely on graphical representation and expert visual assessment, making low-amplitude or borderline abnormalities particularly challenging. Artificial intelligence (AI), including machine-learning (ML) and deep-learning (DL) approaches, has increasingly been applied to SPE, with high performance reported for automated recognition of established abnormalities, particularly M-proteins, i.e., monoclonal immunoglobulins or immunoglobulin fragments produced by clonal plasma cells. However, most models have been developed against predefined diagnostic targets and evaluated using expert interpretation, immunofixation, or immunotyping as reference standards. Improved recognition of known abnormalities should therefore not be equated with discovery of additional clinically meaningful information. Modern electrophoretic platforms generate machine-readable numerical signals that may preserve features not explicitly considered during routine graphical interpretation. This creates the possibility of extending AI-assisted SPE from conventional pattern recognition toward detection of low-amplitude, distributed, or sub-visual signal characteristics. Yet current literature has focused predominantly on algorithmic performance, while the validation pathway required to determine whether additional AI-detected features are biologically meaningful and clinically actionable remains insufficiently defined. Evidence is strongest for automated M-protein recognition, including low-amplitude abnormalities, whereas non-canonical systemic patterns, longitudinal signal analysis, and AI-assisted decomposition of therapeutic monoclonal antibody interference remain exploratory. This critical review addresses this translational gap by evaluating AI applications according to the nature of detected information, strength of supporting evidence, and proximity to clinical implementation. We propose a translational framework addressing four complementary domains: analytical validity, biological validity, clinical validity, and clinical utility. The evidence required in each domain depends on the intended claim and clinical use.
- 19 October 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (20) , 3397
Open AccessHidden Signals in Serum Protein Electrophoresis: Artificial Intelligence from Laboratory Pattern Recognition to Clinical Validation
Serum protein electrophoresis (SPE) remains a central laboratory method for the detection and characterization of monoclonal gammopathies and other dysproteinemic patterns. Despite substantial analytical automation, interpretation still relies largely on graphical representation and expert visual assessment, making low-amplitude or borderline abnormalities particularly challenging. Artificial intelligence (AI), including machine-learning (ML) and deep-learning (DL) approaches, has increasingly been applied to SPE, with high performance reported for automated recognition of established abnormalities, particularly M-proteins, i.e., monoclonal immunoglobulins or immunoglobulin fragments produced by clonal plasma cells. However, most models have been developed against predefined diagnostic targets and evaluated using expert interpretation, immunofixation, or immunotyping as reference standards. Improved recognition of known abnormalities should therefore not be equated with discovery of additional clinically meaningful information. Modern electrophoretic platforms generate machine-readable numerical signals that may preserve features not explicitly considered during routine graphical interpretation. This creates the possibility of extending AI-assisted SPE from conventional pattern recognition toward detection of low-amplitude, distributed, or sub-visual signal characteristics. Yet current literature has focused predominantly on algorithmic performance, while the validation pathway required to determine whether additional AI-detected features are biologically meaningful and clinically actionable remains insufficiently defined. Evidence is strongest for automated M-protein recognition, including low-amplitude abnormalities, whereas non-canonical systemic patterns, longitudinal signal analysis, and AI-assisted decomposition of therapeutic monoclonal antibody interference remain exploratory. This critical review addresses this translational gap by evaluating AI applications according to the nature of detected information, strength of supporting evidence, and proximity to clinical implementation. We propose a translational framework addressing four complementary domains: analytical validity, biological validity, clinical validity, and clinical utility. The evidence required in each domain depends on the intended claim and clinical use.
- Open Access
- 24 September 2026
- Published by MDPI AG in Preprints.org
Hidden Signals in Serum Protein Electrophoresis: Artificial Intelligence from Laboratory Pattern Recognition to Clinical Validation
Serum protein electrophoresis (SPE) remains a central laboratory method for the detection and characterization of monoclonal gammopathies and other dysproteinemic patterns. Despite substantial analytical automation, interpretation still relies largely on graphical representation and expert visual assessment, making low-amplitude or borderline abnormalities particularly challenging. Artificial intelligence (AI), including machine-learning (ML) and deep-learning (DL) approaches, has increasingly been applied to SPE, with high performance reported for automated recognition of established abnormalities, particularly M-proteins, i.e., monoclonal immunoglobulins or immunoglobulin fragments produced by clonal plasma cells. However, most models have been developed against predefined diagnostic targets and evaluated using expert interpretation, immunofixation, or immunotyping as reference standards. Improved recognition of known abnormalities should therefore not be equated with discovery of additional clinically meaningful information. Modern electrophoretic platforms generate machine-readable numerical signals that may preserve features not explicitly considered during routine graphical interpretation. This creates the possibility of extending AI-assisted SPE from conventional pattern recognition toward detection of low-amplitude, distributed, or sub-visual signal characteristics. Yet current literature has focused predominantly on algorithmic performance, while the validation pathway required to determine whether additional AI-detected features are biologically meaningful and clinically actionable remains insufficiently defined. Evidence is strongest for automated M-protein recognition, including low-amplitude abnormalities, whereas non-canonical systemic patterns, longitudinal signal analysis, and AI-assisted decomposition of therapeutic monoclonal antibody interference remain exploratory. This critical review addresses this translational gap by evaluating AI applications according to the nature of detected information, strength of supporting evidence, and proximity to clinical implementation. We propose a translational framework in which additional AI-detected electrophoretic features progress through analytical validity, biological validity, clinical validity, and clinical utility before being considered actionable laboratory information.
- 24 September 2026
- Published by MDPI AG in Preprints.org
Open AccessHidden Signals in Serum Protein Electrophoresis: Artificial Intelligence from Laboratory Pattern Recognition to Clinical Validation
Serum protein electrophoresis (SPE) remains a central laboratory method for the detection and characterization of monoclonal gammopathies and other dysproteinemic patterns. Despite substantial analytical automation, interpretation still relies largely on graphical representation and expert visual assessment, making low-amplitude or borderline abnormalities particularly challenging. Artificial intelligence (AI), including machine-learning (ML) and deep-learning (DL) approaches, has increasingly been applied to SPE, with high performance reported for automated recognition of established abnormalities, particularly M-proteins, i.e., monoclonal immunoglobulins or immunoglobulin fragments produced by clonal plasma cells. However, most models have been developed against predefined diagnostic targets and evaluated using expert interpretation, immunofixation, or immunotyping as reference standards. Improved recognition of known abnormalities should therefore not be equated with discovery of additional clinically meaningful information. Modern electrophoretic platforms generate machine-readable numerical signals that may preserve features not explicitly considered during routine graphical interpretation. This creates the possibility of extending AI-assisted SPE from conventional pattern recognition toward detection of low-amplitude, distributed, or sub-visual signal characteristics. Yet current literature has focused predominantly on algorithmic performance, while the validation pathway required to determine whether additional AI-detected features are biologically meaningful and clinically actionable remains insufficiently defined. Evidence is strongest for automated M-protein recognition, including low-amplitude abnormalities, whereas non-canonical systemic patterns, longitudinal signal analysis, and AI-assisted decomposition of therapeutic monoclonal antibody interference remain exploratory. This critical review addresses this translational gap by evaluating AI applications according to the nature of detected information, strength of supporting evidence, and proximity to clinical implementation. We propose a translational framework in which additional AI-detected electrophoretic features progress through analytical validity, biological validity, clinical validity, and clinical utility before being considered actionable laboratory information.
- Open Access
- 3 July 2026
- Published by MDPI AG in Antibodies
- Vol. 15 (4) , 57
Potential Mechanisms of Partial/Transient Response or Resistance to Daratumumab Therapy: A Focus on Anti-Daratumumab Antibodies and Urinary Daratumumab Loss
Daratumumab, a human IgG1 monoclonal antibody targeting CD38, is widely used in multiple myeloma and AL amyloidosis. Despite its clinical success, many patients fail to achieve durable responses or relapse, underscoring the importance of understanding resistance mechanisms. Drawing on experience from other better-studied monoclonal antibodies, resistance to daratumumab can be categorized into four main mechanisms: (1) reduced CD38 expression on plasma cells; (2) increased expression of complement inhibitory proteins (CD55/CD59), impairing complement-mediated cytotoxicity; (3) reduced drug bioavailability due to urinary loss in non-selective nephrotic syndrome; and (4) the development of neutralizing anti-daratumumab antibodies. Anti-drug antibodies (ADAs) may represent a potential mechanism of treatment failure through effects on pharmacokinetics, efficacy, and safety, even in patients on daratumumab therapy. Seven different trials have tested anti-daratumumab antibodies. Among them, anti-daratumumab antibodies were identified in only 0–2.4% of patients, and only in a small portion of these has it been proven to be neutralizing. Overall, ADAs appear rare, but these findings are likely underestimated due to short follow-up and suboptimal timing of assessment. In conclusion, standardized ADA monitoring, particularly months after treatment interruption or in cases of inadequate response or infusion-related reactions, may improve patient management and therapeutic outcomes.
- 3 July 2026
- Published by MDPI AG in Antibodies
- Vol. 15 (4) , 57
Open AccessPotential Mechanisms of Partial/Transient Response or Resistance to Daratumumab Therapy: A Focus on Anti-Daratumumab Antibodies and Urinary Daratumumab Loss
Daratumumab, a human IgG1 monoclonal antibody targeting CD38, is widely used in multiple myeloma and AL amyloidosis. Despite its clinical success, many patients fail to achieve durable responses or relapse, underscoring the importance of understanding resistance mechanisms. Drawing on experience from other better-studied monoclonal antibodies, resistance to daratumumab can be categorized into four main mechanisms: (1) reduced CD38 expression on plasma cells; (2) increased expression of complement inhibitory proteins (CD55/CD59), impairing complement-mediated cytotoxicity; (3) reduced drug bioavailability due to urinary loss in non-selective nephrotic syndrome; and (4) the development of neutralizing anti-daratumumab antibodies. Anti-drug antibodies (ADAs) may represent a potential mechanism of treatment failure through effects on pharmacokinetics, efficacy, and safety, even in patients on daratumumab therapy. Seven different trials have tested anti-daratumumab antibodies. Among them, anti-daratumumab antibodies were identified in only 0–2.4% of patients, and only in a small portion of these has it been proven to be neutralizing. Overall, ADAs appear rare, but these findings are likely underestimated due to short follow-up and suboptimal timing of assessment. In conclusion, standardized ADA monitoring, particularly months after treatment interruption or in cases of inadequate response or infusion-related reactions, may improve patient management and therapeutic outcomes.
- Open Access
- 24 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (13) , 1970
A Step Forward in Post-Mortem Interval Estimation: Multivariate Analysis of Ammonium, Albumin, and Potassium Levels in Vitreous Humor
Background/Objectives: Accurate post-mortem interval (PMI) estimation remains challenging in forensic pathology. Although potassium (K+) is the most well-validated single biomarker in vitreous humor (VH), multivariate approaches may enhance precision by capturing the complex cascade of post-mortem biochemical changes. This study aimed to develop and validate a multivariate PMI estimation model incorporating three biochemical markers—potassium, ammonium (NH4+), and albumin (ALB)—in vitreous humor using automated clinical chemistry platforms for practical forensic application. Methods: Vitreous humor samples from 38 autopsy cases with documented PMIs (39.5–285 h; mean, 105.5 h) were analyzed for K+ (Cobas C8000), NH4+ (Cobas C8000), and ALB (Immage 800 nephelometry). Univariate and multivariate regression analyses were performed, with the residual standard error (RSE) as the primary measure of accuracy. Model validation was conducted by back-calculating PMI in four samples completely distinct from the training cohort. Results: All three analytes demonstrated strong individual correlations with PMI (R2: K+ = 0.88, ALB = 0.78, NH4+ = 0.69; all p < 0.001). The multivariate regression model [PMI = 40.25[Alb] + 0.01573[NH4+] + 5.339[K+] − 53.032] yielded an RMSE of ±15.5 h (MSE = 240.25 h2), outperforming potassium-only models (RMSE = ±22.6 h). Although NH4+ showed limited statistical significance in the multivariate model (p = 0.128), its inclusion improved overall predictive accuracy. External validation in an independent cohort of four subjects (distinct from the 38 subjects in the training set) demonstrated a mean absolute error (MAE) of 20.4 h. Conclusions: The multivariate approach combining K+, NH4+, and ALB in VH improves PMI estimation accuracy compared with single-marker methods. The use of automated clinical chemistry platforms enhances reproducibility and facilitates practical implementation in forensic laboratories.
- 24 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (13) , 1970
Open AccessA Step Forward in Post-Mortem Interval Estimation: Multivariate Analysis of Ammonium, Albumin, and Potassium Levels in Vitreous Humor
Background/Objectives: Accurate post-mortem interval (PMI) estimation remains challenging in forensic pathology. Although potassium (K+) is the most well-validated single biomarker in vitreous humor (VH), multivariate approaches may enhance precision by capturing the complex cascade of post-mortem biochemical changes. This study aimed to develop and validate a multivariate PMI estimation model incorporating three biochemical markers—potassium, ammonium (NH4+), and albumin (ALB)—in vitreous humor using automated clinical chemistry platforms for practical forensic application. Methods: Vitreous humor samples from 38 autopsy cases with documented PMIs (39.5–285 h; mean, 105.5 h) were analyzed for K+ (Cobas C8000), NH4+ (Cobas C8000), and ALB (Immage 800 nephelometry). Univariate and multivariate regression analyses were performed, with the residual standard error (RSE) as the primary measure of accuracy. Model validation was conducted by back-calculating PMI in four samples completely distinct from the training cohort. Results: All three analytes demonstrated strong individual correlations with PMI (R2: K+ = 0.88, ALB = 0.78, NH4+ = 0.69; all p < 0.001). The multivariate regression model [PMI = 40.25[Alb] + 0.01573[NH4+] + 5.339[K+] − 53.032] yielded an RMSE of ±15.5 h (MSE = 240.25 h2), outperforming potassium-only models (RMSE = ±22.6 h). Although NH4+ showed limited statistical significance in the multivariate model (p = 0.128), its inclusion improved overall predictive accuracy. External validation in an independent cohort of four subjects (distinct from the 38 subjects in the training set) demonstrated a mean absolute error (MAE) of 20.4 h. Conclusions: The multivariate approach combining K+, NH4+, and ALB in VH improves PMI estimation accuracy compared with single-marker methods. The use of automated clinical chemistry platforms enhances reproducibility and facilitates practical implementation in forensic laboratories.
- Open Access
- 29 October 2021
- Published by MDPI AG in Brain Sciences
- Vol. 11 (11) , 1444
Cerebrospinal Fluid IgM and Oligoclonal IgG Bands in Multiple Sclerosis: A Meta-Analysis of Prevalence and Prognosis
The presence of intrathecal IgM synthesis (ITMS) has been associated with an aggressive multiple sclerosis (MS) clinical course. In the present systematic review, we aimed at assessing the prevalence of ITMS among different MS phenotypes. Moreover, we aimed at quantifying the risk of a second relapse in ITMS positive and oligoclonal IgG bands (OCGBs)-positive patients. We selected clinical studies reporting the ITMS prevalence assessed as oligoclonal IgM Bands (OCMBs), lipid-specific OCMBs (LS-OCMBs), and/or as an intrathecal IgM production > 0% (IgMLoc, Reiber formula). The overall prevalence of ITMS was higher in relapsing-remitting (RR) than clinically isolated syndrome (CIS) patients (40.1% versus 23.8%, p < 0.00001), while was in line with that detected in primary progressive MS (PPMS, 26.7%). Almost all patients (98%) with ITMS had also OCGBs. The risk of having a second relapse was higher in OCGBs positive patients (HR = 2.18, p = 0.007) but much higher in ITMS positive patients (HR = 3.62, p = 0.0005). This study revealed that the prevalence of ITMS is higher in RRMS patients. It suggests that the risk of having a second relapse, previously ascribed to OCGBs, may, to a certain extent, be related to the presence of intrathecal IgM.
- 29 October 2021
- Published by MDPI AG in Brain Sciences
- Vol. 11 (11) , 1444
Open AccessCerebrospinal Fluid IgM and Oligoclonal IgG Bands in Multiple Sclerosis: A Meta-Analysis of Prevalence and Prognosis
The presence of intrathecal IgM synthesis (ITMS) has been associated with an aggressive multiple sclerosis (MS) clinical course. In the present systematic review, we aimed at assessing the prevalence of ITMS among different MS phenotypes. Moreover, we aimed at quantifying the risk of a second relapse in ITMS positive and oligoclonal IgG bands (OCGBs)-positive patients. We selected clinical studies reporting the ITMS prevalence assessed as oligoclonal IgM Bands (OCMBs), lipid-specific OCMBs (LS-OCMBs), and/or as an intrathecal IgM production > 0% (IgMLoc, Reiber formula). The overall prevalence of ITMS was higher in relapsing-remitting (RR) than clinically isolated syndrome (CIS) patients (40.1% versus 23.8%, p < 0.00001), while was in line with that detected in primary progressive MS (PPMS, 26.7%). Almost all patients (98%) with ITMS had also OCGBs. The risk of having a second relapse was higher in OCGBs positive patients (HR = 2.18, p = 0.007) but much higher in ITMS positive patients (HR = 3.62, p = 0.0005). This study revealed that the prevalence of ITMS is higher in RRMS patients. It suggests that the risk of having a second relapse, previously ascribed to OCGBs, may, to a certain extent, be related to the presence of intrathecal IgM.